Compass Therapeutics (CMPX) Equity Ratio: 2023-2025
Historic Equity Ratio for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to 0.91.
- Compass Therapeutics' Equity Ratio fell 2.32% to 0.91 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.91, marking a year-over-year decrease of 2.32%. This contributed to the annual value of 0.89 for FY2024, which is 5.80% down from last year.
- Compass Therapeutics' Equity Ratio amounted to 0.91 in Q3 2025, which was up 13.48% from 0.80 recorded in Q2 2025.
- Compass Therapeutics' 5-year Equity Ratio high stood at 0.97 for Q1 2024, and its period low was 0.80 during Q2 2025.
- Over the past 3 years, Compass Therapeutics' median Equity Ratio value was 0.93 (recorded in 2023), while the average stood at 0.91.
- Per our database at Business Quant, Compass Therapeutics' Equity Ratio increased by 4.54% in 2024 and then decreased by 14.93% in 2025.
- Over the past 3 years, Compass Therapeutics' Equity Ratio (Quarterly) stood at 0.95 in 2023, then dropped by 5.80% to 0.89 in 2024, then fell by 2.32% to 0.91 in 2025.
- Its last three reported values are 0.91 in Q3 2025, 0.80 for Q2 2025, and 0.84 during Q1 2025.